S&P Futures
3,923.75 +20.00 (+0.51%) Dow Futures
31,591.00 +170.00 (+0.54%) Nasdaq Futures
12,093.75 +53.25 (+0.44%) Russell 2000 Futures
1,782.60 +12.80 (+0.72%) Crude Oil
111.37 +1.80 (+1.64%) Gold
1,823.60 -1.20 (-0.07%)
Synthetic Biologics, Inc. (SYN)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.1938 |
| Open | 0.2150 |
| Bid | 0.1925 x 1800 |
| Ask | 0.1951 x 1300 |
| Day's Range | 0.1900 - 0.2150 |
| 52 Week Range | 0.1800 - 0.6400 |
| Volume | |
| Avg. Volume | 920,264 |
| Market Cap | 30.911M |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.63 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SYN
Related Research
- Synthetic Biologics, Inc.Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.RatingFair ValueEconomic Moat7 days agoMorningstar
- GlobeNewswire
Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results
-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- - Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose clinical trial- -Formed Scientific Advisory Board and strengthened the leadership team
- Benzinga
Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers
Synthetic Biologics Inc (NYSE: SYN) has announced safety data from its Phase 1 multiple ascending dose (MAD) trial of SYN-020 intestinal alkaline phosphatase (IAP). The Phase 1 MAD study enrolled 32 healthy adult volunteers into four cohorts with SYN-020 administered orally in doses ranging from 5 mg to 75 mg twice daily for 14 days, with a follow-up evaluation at day 35. SYN-020 is a recombinant bovine IAP formulated for oral delivery to the small intestine and designed to diminish fat absorpti
- GlobeNewswire
Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial
-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind multiple ascending dose (MAD) clinical trial of SYN-020 intestinal alkaline phosphatase (IAP). The
